Thrombosis Journal最新文献

{"title":"The risk factors of liver cirrhosis complicated with portal vein thrombosis and the efficacy and safety of anticoagulant therapy: a meta analysis.","authors":"Le Zhang, Xia Wang, Pu Ming, Li-Na Ma, Wanlong Ma, Xiang-Chun Ding","doi":"10.1186/s12959-025-00725-9","DOIUrl":"https://doi.org/10.1186/s12959-025-00725-9","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the risk factors of liver cirrhosis complicated with portal vein thrombosis and the efficacy and safety of anticoagulant therapy.</p><p><strong>Methods: </strong>Relevant literature was searched through PubMed, Cochrane library, Embase, Web of Science, Wanfang Medical Network and CNKI databases, and eligible literature was included. QUADS scale was used to evaluate the quality of the included literatures, and Stata15.1 software was used for meta-analysis and statistical processing.</p><p><strong>Results: </strong>For risk factors analysis for cirrhosis with Portal vein thrombosis, 19 literatures were included, including 1563 patients with cirrhosis with portal vein thrombosis and 2579 patients with cirrhosis without portal vein thrombosis, all of which were not treated with anticoagulation. The results of meta-analysis showed that compared with the PVT group, there was no significant difference in creatinine(Scr,MD = 0.09,95%CI: -0.03-0.22,P = 0.132)and total bilirubin(TBIL,MD = -0.00, 95%CI: -0.10 ~ 0.09,P = 0.948).There was significant difference in albumin(ALB,MD = -0.32, 95%CI:-0.43-0.21,P = 0.000)and PLT(PLT, MD = 0.15, 95%CI: 0.05-0.26, P = 0.004).And there was also no difference in hypertension history (OR = 0.78,95%CI:0.59 ~ 1.03,P = 0.079). In the study on the anticoagulant effect and safety of liver cirrhosis complicated with portal vein thrombosis, a total of 9 literatures were included. Among them,497 patients with liver cirrhosis complicated by portal vein thrombosis are treated with Anticoagulation treatment, and 633 patients with cirrhosis complicated by portal vein thrombosis without anticoagulation treatment. The analysis results showed that the thrombus recanalization situation of liver cirrhosis complicated with portal vein thrombosis after anticoagulation treatment was better than that of patients without anticoagulation (OR = 4.052,95%CI: 2.737-6.000,P = 0.000),and there was no significant difference in the occurrence of bleeding events between patients with anticoagulation and those without anticoagulation (OR = 1.017, 95%CI:0.735-1.407,P = 0.920). The Stata15.1Egger test showed no significant publication bias for all the results(P > 0.05).</p><p><strong>Conclusions: </strong>Patients with liver cirrhosis complicated with low platelet and low albumin are more likely to develop PVT. Anticoagulation is helpful and safe for thrombolysis in patients with liver cirrhosis complicated with PVT.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"43"},"PeriodicalIF":2.6,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence and risk factors of pulmonary embolism in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.","authors":"Mingzhu Li, Yeqian Jiang, Ying Xu, Qianbing Li","doi":"10.1186/s12959-025-00728-6","DOIUrl":"https://doi.org/10.1186/s12959-025-00728-6","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;An increased prevalence of PE has been found in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD). Early identification of risk factors for the development of PE in patients with AECOPD and intervention is important. Therefore, we comprehensively pool and analyze the prevalence and risk factors of PE among patients experiencing AECOPD, aiming to provide valuable insights for clinical-based diagnostic determination and prevention of PE in the AECOPD patient population.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A systematic literature search was conducted for studies reporting the incidence and risk factors for PE in patients with AECOPD. Study quality was assessed using the modified Newcastle-Ottawa Quality Assessment Scale. The degree of heterogeneity was assessed by the I&lt;sup&gt;2&lt;/sup&gt; statistic. The publication bias (studies ≥ 10) was evaluated using Egger's test.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among the 1421 studies initially retrieved, 22 articles were ultimately selected and incorporated into the analysis. Based on the meta-analysis and the review's updated findings, the prevalence of PE in AECOPD is 17.82% (95% CI 12.72%-23.57%, P&lt;0.001). The following factors were identified as risk factors for PE among patients with AECOPD: age(weighted mean difference [WMD] 2.0119, 95% CI 0.7126-3.3133, I&lt;sup&gt;2&lt;/sup&gt; = 51.8%, P = 0.02), males(odds ratio [OR] 0.9528, 95% CI 0.6869-1.3216, I&lt;sup&gt;2&lt;/sup&gt; = 65.0%, P&lt;0.001), obesity(OR 1.3086, 95% CI 0.1895-9.0385, I&lt;sup&gt;2&lt;/sup&gt; = 74.5%, P = 0.02), malignant disease(OR 1.5902, 95%CI 0.9689-2.6097, I&lt;sup&gt;2&lt;/sup&gt; = 54.7%, P = 0.03), hypertension(OR 1.0663, 95%CI 0.7920-1.4355, I&lt;sup&gt;2&lt;/sup&gt; = 57.7%, P = 0.009), immobilization ≥ 3d(OR 3.9158, 95% CI 1.0925-14.0354, I&lt;sup&gt;2&lt;/sup&gt; = 91.6%, P&lt;0.001), edema of lower limb(OR 2.1558, 95% CI 1.3365-3.4773, I&lt;sup&gt;2&lt;/sup&gt; = 75.4%, P&lt;0.001), pulmonary hypertension(OR 1.3146, 95%CI 0.7481-2.3100, I&lt;sup&gt;2&lt;/sup&gt; = 70.1%, P = 0.04), cough(OR 0.7084, 95%CI 0.1304-3.8497, I&lt;sup&gt;2&lt;/sup&gt; = 88.8%, P&lt;0.001), purulent sputum(OR 0.7570, 95%CI 0.4005-1.4309, I&lt;sup&gt;2&lt;/sup&gt; = 61.9%, P = 0.049), and D-dimer(WMD 0.8619, 95%CI 0.0449-1.6789, I&lt;sup&gt;2&lt;/sup&gt; = 91.4%, P&lt;0.001), C-reactive protein(CRP)(WMD 0.8852, 95%CI -4.0639-5.8344, I&lt;sup&gt;2&lt;/sup&gt; = 76.4%, P = 0.005) or fibrinogen(WMD 0.8663, 95%CI -0.2572-1.9898, I&lt;sup&gt;2&lt;/sup&gt; = 92.2%, P&lt;0.001) levels. Clinical risk factors(including S1Q3 pattern on electrocardiograph(ECG), hospital stay and home oxygen therapy) showed no significant association with the occurrence of PE (P&gt;0.05).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This updated meta-analysis and systematic review revealed that the prevalence of pulmonary embolism in the AECOPD was 17.82%. This figure may vary depending on how the diagnostic procedure is carried out. Age, males, obesity, malignant disease, hypertension, immobilization ≥ 3d, edema of lower limb, pulmonary hypertension, cough, purulent sputum, and D-dimer, CRP or fibrinogen ","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"42"},"PeriodicalIF":2.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Von Willebrand disease (VWD) and pregnancy: a comprehensive overview.","authors":"Hamed Soleimani Samarkhazan, Mohammad Navid Khaksari, Ali Rahmati, Mahsa Loran Esfahani, Amin Solouki, Mojtaba Aghaei","doi":"10.1186/s12959-025-00727-7","DOIUrl":"https://doi.org/10.1186/s12959-025-00727-7","url":null,"abstract":"<p><p>Von Willebrand disease (VWD) is a hereditary bleeding disorder characterized by a quantitative or qualitative deficiency of von Willebrand factor (VWF). Pregnancy significantly impacts hemostasis, leading to a hypercoagulable state. However, women with VWD experience unique challenges due to the interplay between pregnancy-related hormonal changes and VWF deficiencies. This review delves into the intricate relationship between VWD and pregnancy. We explored the physiological changes that occur during pregnancy, including hormonal fluctuations, hemodilution, and alterations in platelet-VWF interactions. We discuss how these changes can exacerbate bleeding tendencies in women with VWD, particularly during childbirth and the postpartum period. This review highlights the increased risk of postpartum hemorrhage (PPH) in women with VWD and the potential for severe maternal morbidity and mortality. We examine the various types of VWD and their specific implications for pregnancy outcomes. Additionally, we discuss the challenges associated with diagnosing and managing VWD during pregnancy, as well as the importance of prenatal counseling and careful monitoring. The management of VWD during pregnancy involves a multidisciplinary approach, including the use of prophylactic treatments, such as desmopressin and tranexamic acid, as well as factor replacement therapy when necessary. Careful planning of delivery, including the choice of delivery mode and the timing of interventions, is essential to minimize bleeding complications. By understanding the complexities of VWD during pregnancy and implementing appropriate management strategies, healthcare providers can significantly improve the outcomes for women with VWD and their offspring.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"41"},"PeriodicalIF":2.6,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12036306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of magnetic resonance angiography combined with serum ischemia-modified albumin for secondary cerebral infarction after transient ischemic attack.","authors":"Lige Liu, Qiuyue Yan, Jingyi Ai, Rudong Jiao, Meng Li","doi":"10.1186/s12959-025-00717-9","DOIUrl":"https://doi.org/10.1186/s12959-025-00717-9","url":null,"abstract":"<p><strong>Objective: </strong>This study investigated the diagnostic value of magnetic resonance angiography (MRA) combined with serum ischaemia-modifier albumin (IMA) testing in predicting secondary cerebral infarction (CI) following transient ischemic attack (TIA).</p><p><strong>Methods: </strong>All TIA patients underwent MRA and IMA level assessments, along with ABCD² scoring (a TIA risk stratification tool). Patients were categorized into secondary CI and non-CI groups based on the occurrence of CI within a 90-day follow-up period. Vessel stenosis, serum IMA levels, the predictive value of MRA and IMA levels for secondary CI after TIA, and the independent factors associated with secondary CI in TIA patients were analyzed.</p><p><strong>Results: </strong>The high-risk and intermediate-risk groups showed a higher proportion of moderate-severe vessel stenosis and elevated IMA levels compared to the low-risk group, with IMA levels significantly higher in the high-risk group than in the intermediate-risk group (P < 0.05). The secondary CI group exhibited a greater proportion of moderate-severe vessel stenosis and higher IMA levels compared to non-CI group (P < 0.05). The combined predictive model using MRA and IMA demonstrated a significantly higher area under the curve (AUC = 0.908) compared to MRA alone (AUC = 0.798; z = 3.083, P = 0.002), but only slightly higher than IMA alone (AUC = 0.875; z = 1.226, P = 0.220). Independent factors associated with secondary CI included advanced age, moderate-severe vessel stenosis, ABCD² scores, and elevated IMA levels (OR > 1, P < 0.05).</p><p><strong>Conclusion: </strong>Changes in MRA and IMA levels were correlated with disease severity in TIA patients. MAR combined with serum IMA demonstrated high predictive efficacy for secondary CI after TIA, making it a valuable tool for CI risk assessment. Independent factors associated with secondary CI included advanced age, moderate-severe vessel stenosis, intermediate-high-risk ABCD² scores, and elevated IMA levels.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"40"},"PeriodicalIF":2.6,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12036210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal relationship between atherosclerosis and inflammatory bowel disease risk: a two-sample Mendelian randomization study.","authors":"Wenjuan Guo, Na Peng, Shiyu Du","doi":"10.1186/s12959-025-00722-y","DOIUrl":"https://doi.org/10.1186/s12959-025-00722-y","url":null,"abstract":"<p><strong>Objective: </strong>This study was to evaluate the causal associations of atherosclerosis with the risk of inflammatory bowel disease (IBD), and its subtypes [ulcerative colitis (UC) and Crohn's disease (CD)]: a two-sample Mendelian randomization study.</p><p><strong>Materials and methods: </strong>Single nucleotide polymorphism (SNPs) associated with atherosclerosis including CPAmax, CPSmax, brachial-femoral pulse wave velocity (bfPWV), coronary atherosclerosis, cerebral atherosclerosis, peripheral atherosclerosis, coronary artery disease (CAD) and ischemic stroke (IS) were identified from previous genome-wide association studies (GWAS). SNPs were strictly selected to fulfill the MR assumptions. The causal links between atherosclerosis and IBD were evaluated using inverse-variance weighted (IVW) as the primary method. Leave-one-out analysis was utilized to evaluate whether the outcomes were attributable to any individual SNP correlated to sex hormones. The estimates were subjected to odds ratio (OR) and 95% confidence interval (CI).</p><p><strong>Results: </strong>The results of IVW revealed that coronary atherosclerosis had causal association with increased risk of CD (OR = 1.162, 95%CI: 1.031-1.311). The causal association was also observed in IS with CD (OR = 1.376, 95%CI: 1.011-1.873) and UC (OR = 1.508, 95%CI: 1.153-1.971). Leave-one-out analysis indicated that no single SNP can affect the associations of CAD with IBD, CD, and UC, coronary atherosclerosis with CD, as well as IC with CD and UC.</p><p><strong>Conclusions: </strong>Coronary atherosclerosis was causally related to CD, and IS had causal relationship with CD and UC. The finding might provide evidence for future exploration of the etiology for IBD.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"39"},"PeriodicalIF":2.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coagulopathy as a predictor of the effectiveness of tranexamic acid in severe blunt trauma: a multicenter retrospective study.","authors":"Yuki Takahashi, Mineji Hayakawa, Yuki Itagaki, Kota Ono, Daisuke Kudo, Shigeki Kushimoto","doi":"10.1186/s12959-025-00723-x","DOIUrl":"https://doi.org/10.1186/s12959-025-00723-x","url":null,"abstract":"<p><strong>Background: </strong>Tranexamic acid (TXA) reduces mortality in severe trauma cases. However, the relationships between TXA administration and coagulation/fibrinolysis abnormalities are unclear. We performed a retrospective observational study to investigate relationships between mortality and coagulation/fibrinolysis abnormalities of patients on arrival at the emergency department and whether TXA is more effective in patients with severe trauma who have coagulation/fibrinolysis abnormalities than in those who do not.</p><p><strong>Methods: </strong>Data was collected from 15 tertiary emergency and critical care centers in Japan. Adult patients with blunt trauma and an Injury Severity Score of ≥ 16 were included in the study. Patients were categorized into two groups: the TXA group received TXA within 3 h of arrival, and the non-TXA group did not.</p><p><strong>Results: </strong>Overall, 790 patients were included (TXA group, 276; non-TXA group, 514). In cubic spline curves for relationships between mortality and coagulation/fibrinolysis variables on arrival, odds for mortality increased and plateaued with a prothrombin time-international normalized ratio ≥ 1.2; the disseminated intravascular coagulation (DIC) score showed a marked odds increase when > 4 points. Odds increased and plateaued from an activated partial thromboplastin time (APTT) of ≥ 35 s and gradually increased as fibrinogen decreased from 250 mg/dL. Fibrinogen and fibrin degradation products (FDP) and D-dimer exhibited upward-sloping curves. In cubic spline curves for relationships between the effectiveness of TXA administration and coagulation/fibrinolysis variables on arrival, a favorable effect on mortality was observed with TXA administration when fibrinogen was ≤ 200 mg/dL or when the DIC score was ≥ 4 points; FDP, ≥ 50 µg/mL; D-dimer, ≥ 30 µg/mL; or APTT, ≥ 35 s. In each threshold subgroup, interactions between TXA administration and in-hospital mortality were observed.</p><p><strong>Conclusions: </strong>TXA demonstrates increased effectiveness in patients with traumatic coagulation/fibrinolysis abnormalities.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"37"},"PeriodicalIF":2.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clopidogrel vs. ticagrelor in ST-elevation myocardial infarction complicated by cardiogenic shock undergoing primary PCI : Findings from a National, multicenter registry.","authors":"Can Zhou, Minghui Zhang, Zixu Zhao, Enze Li, Yichen Zhao, Wei Luo, Keyang Zheng, Yu Liu, Chengqian Yin, Xinyong Zhang, Hai Gao, Dong Zhao, Changsheng Ma","doi":"10.1186/s12959-025-00721-z","DOIUrl":"https://doi.org/10.1186/s12959-025-00721-z","url":null,"abstract":"<p><strong>Background: </strong>Although ticagrelor is recommended as opposed to clopidogrel in antiplatelet strategy for patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI), evidence is limited in patients with cardiogenic shock (CS).</p><p><strong>Objective: </strong>This study aims to evaluate the comparative efficacy and safety profile of ticagrelor and clopidogrel in patients with STEMI-CS undergoing pPCI.</p><p><strong>Methods: </strong>Using data from a nationwide, multicenter registry, eligible patients were stratified into clopidogrel or ticagrelor based on the choice of P2Y₁₂ inhibitors within 24 h of first medical contact. Multivariable-adjusted Cox regression analyses, along with Cox models adjusted for propensity score matching and inverse probability treatment weighting were conducted to compare outcomes between ticagrelor and clopidogrel. The efficacy and safety outcomes were in-hospital all-cause mortality and major bleeding.</p><p><strong>Results: </strong>Among 729 STEMI-CS patients in our cohort, 403 received clopidogrel and 326 received ticagrelor. Multivariable-adjusted Cox regression analyses showed that ticagrelor was not associated with a significant difference in all-cause mortality (adjusted HR: 1.04; 95% CI: 0.69-1.56; p = 0.840) and major bleeding (adjusted HR: 1.30; 95% CI: 0.62-2.76; p = 0.489) compared to clopidogrel. Consistent results were found in the analyses adjusted by propensity score matching and inverse probability of treatment weighting.</p><p><strong>Conclusions: </strong>Our findings suggest that the choice of either ticagrelor or clopidogrel was feasible as a P2Y₁₂ inhibitor for dual anti-platelet strategy in STEMI-CS patients undergoing pPCI, as no significant difference between these two agents was observed in all-cause mortality and major bleeding during hospitalization.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT02306616. Registered 29 November 2014.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"38"},"PeriodicalIF":2.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-associated venous thromboembolism: a comprehensive review.","authors":"Tingting Wan, Jia Song, Dapeng Zhu","doi":"10.1186/s12959-025-00719-7","DOIUrl":"https://doi.org/10.1186/s12959-025-00719-7","url":null,"abstract":"<p><p>It has been 200 years since the first case of cancer-associated thrombosis (CAT) was reported. Venous thromboembolism (VTE) remains a leading cause of morbidity and mortality in cancer patients. Malignant tumors interact with the coagulation system in complex ways. CAT continues to pose a significant challenge in clinical practice. The risk factors for CAT are complex and multifactorial, primarily including patient, cancer, and therapy-related factors. We have introduced assessment models for CAT and bleeding risk, but the performance of these models has been less than satisfactory. Currently, the main anticoagulant drugs for treating CAT include vitamin K antagonists (VKAs), low molecular weight heparin (LMWH), and direct oral anticoagulants (DOACs). We have provided a detailed overview of the advantages and disadvantages of these three types of drugs and suggestions on choosing the appropriate type of medication for different clinical scenarios. CAT incidence, pathophysiology, risk factors, risk prediction models, and recent advancements in treatment and management are summarized in this review.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"35"},"PeriodicalIF":2.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The proportion of young male hemophilia patients who underwent ultrasound examinations: an observational study using a nationwide claims database.","authors":"Yosuke Uchihashi, Tatsuya Noda, Yusuke Inagaki, Kenichi Ogiwara, Yuya Mawarikado, Yuichi Nishioka, Tomoya Myojin, Kagehiro Amano, Akira Shirahata, Keiji Nogami, Akira Kido, Tomoaki Imamura","doi":"10.1186/s12959-025-00724-w","DOIUrl":"https://doi.org/10.1186/s12959-025-00724-w","url":null,"abstract":"<p><strong>Background: </strong>Advances in hemophilia treatment have reduced bleeding episodes in patients with hemophilia (PWH) and improved their musculoskeletal prognosis; however, complete prevention of musculoskeletal disorders has not been achieved. Recently, the usefulness of ultrasound (US) examinations in the musculoskeletal assessment of PWH has been reported, but the actual use of US has been suggested to be limited. The aim of this study was to clarify the extent to which US is being performed on young male PWH at medical institutions in Japan.</p><p><strong>Methods: </strong>This was an observational study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. We identified almost all male PWH aged under 30 years who were prescribed hemostatic agents between 2015 and 2021 in Japan. For each year, we calculated the proportion of PWH who underwent US and, as a sensitivity analysis, the proportion of PWH who underwent US examinations for musculoskeletal disease. The Cochran‒Armitage trend test was used to examine changes in the number of PWH who underwent US examinations over the observation period. The Lorenz curves and Gini coefficients were calculated from the proportion of US examinations performed at each medical institution annually.</p><p><strong>Results: </strong>A total of 2137-2483 male PWH younger than 30 years were identified annually. The annual proportion of PWH who underwent US ranged from 6.1 to 12.9%. By age group, the annual proportions of US were 6.7-14.4%, 8.1-16.6%, and 2.0-8.7% for 0-9, 10-19, and 20-29 years, respectively. The annual proportions of musculoskeletal US were 2.9-7.7%. The proportion of PWH who underwent US increased significantly over the seven-year period; however, it varied by medical institution (Gini coefficients 0.85-0.92).</p><p><strong>Conclusions: </strong>The use of US for young PWH is becoming more widespread in Japan. However, US is performed at different rates among medical institutions.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"34"},"PeriodicalIF":2.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism.","authors":"Masashi Yoshida, Kentaro Ejiri, Naoaki Matsuo, Takanori Naito, Kazuhiro Kuroda, Koji Tokioka, Kunihiko Hatanaka, Ryohei Fujimoto, Hidenaru Yamaoka, Yutaka Kajikawa, Kazuki Suruga, Hiroki Sugiyama, Tsuyoshi Miyaji, Yoshimasa Morimoto, Nobuhiro Okamura, Toshihiro Sarashina, Satoshi Akagi, Toru Miyoshi, Kazufumi Nakamura, Hiroshi Ito, Shinsuke Yuasa","doi":"10.1186/s12959-025-00720-0","DOIUrl":"https://doi.org/10.1186/s12959-025-00720-0","url":null,"abstract":"<p><strong>Background: </strong>Edoxaban, a direct oral anticoagulant (DOAC), is a first-line treatment for venous thromboembolism (VTE) and the suppression of VTE recurrence. In patients with cancer, however, recurrent VTE after DOAC treatment may be more common than in noncancer patients. To evaluate our hypothesis that the anticoagulation effect of edoxaban is lower in VTE patients with cancer than in noncancer patients.</p><p><strong>Methods: </strong>This study was a prospective, multicenter, observational study including patients treated with edoxaban for VTE in Japan. The primary outcome was the difference in the prothrombin time (PT), activated partial thromboplastin time (APTT), and D-dimer level at 5 h after initial edoxaban administration between the cancer and noncancer groups. An additional outcome was the longitudinal change in PT and APTT from 5 h to overnight after edoxaban administration. The incidence of adverse events was further investigated.</p><p><strong>Results: </strong>PT and APTT at 5 h after initial edoxaban administration were not significantly different between the cancer (n = 84) and noncancer groups (n = 138) (e.g., log-transformed APTT 3.55 vs. 3.55, p = 0.45). However, D-dimer in the cancer groups was significantly greater than that in the noncancer groups (log-transformed 1.83 vs. 1.79, p = 0.009). PT and APTT significantly decreased from 5 h to overnight after edoxaban, but a similar pattern was observed in each group. All adverse events after edoxaban administration were also similar between patients with cancer and noncancer.</p><p><strong>Conclusion: </strong>PT and APTT after edoxaban administration were similar between VTE patients with cancer and noncancer groups, suggesting that edoxaban has anticoagulation effects on cancer-associated VTE similar to those of noncancer patients.</p><p><strong>Trial registration: </strong>UMIN000041973; Registration Date: 2020.10.5.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"36"},"PeriodicalIF":2.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}